Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-Line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkins Lymphoma: A Randomized, Controlled, Phase III Comparative Trial.

Trial Profile

Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-Line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkins Lymphoma: A Randomized, Controlled, Phase III Comparative Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Pixantrone (Primary) ; Etoposide; Gemcitabine; Ifosfamide; Mitoxantrone; Oxaliplatin; Rituximab; Vinorelbine
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms EXTEND
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 12 Mar 2018 A protocol was amended to exclude patients with no previous treatment with rituximab in countries where it was commercially available, according to results published in the Clinical Drug Investigation.
    • 12 Mar 2018 Results of post-hoc analysis assessing long-term response and remission (n=17) published in the Clinical Drug Investigation
    • 17 Jun 2013 Results from post-hoc sub-set analyses presented at the 18th Congress of the European Hematology Association, according to a Cell Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top